PUBLISHED- results from our completed IIT combining atezolizumab, varlilumab & palliative RT for refractory NSCLC. Learnt valuable insights on leveraging biomarkers to target IO resistance JTO & JTO CRR #CRR Salma Jabbour City of Hope Department of Medical Oncology Rutgers Cancer Institute jtocrr.org/article/S2666-…

Major academic publishers' revenue and what they pay authors and reviewers: Revenue: Elsevier: $3.9 billion Springer Nature: $2 billion Taylor & Francis: $800M Wiley: $1.8 billion They pay: Academic authors: $0 Peer reviewers: $0

If anybody wants to know why Gen X is always mad, it's because we had to replace our record collections with a tape collection that we had to replace with a CD collection that we had to replace with an MP3 collection, and now we need a subscription to listen to music.

Too long #cancer was #tissue only. Article shows tech that ⬆️ #crcsm outcomes by combining biomarkers: 🧬 gene signatures 📈 spatial analysis 🦠 single cell Leading to better: 📉 Predictive 🚫 Preventative 🎯 Personalized Medicine #GIonc OncoAlert🚨 mdpi.com/2072-6694/16/3…

When it comes to cancer, we don’t have time to wait. We have to be impatient for our patients. In the latest Coping with Cancer, I shared my thoughts on the meaningful advances NCI has made since last year, as well as new opportunities to be optimistic about. spr.ly/6018mRRdA

Jacob did great job articulating our viewpoint,

In episode 2 of #BetterListeningforBetterHealth, CREATION CEO Daniel Ghinn asked Shaalan Beg MD MBA FASCO about skepticism towards the use of #AI in decision making among healthcare professionals. 👉 Listen to the full episode now to discover his thoughts Youtube: hubs.la/Q02Mm7ts0

How the same cancer driver mutations can manifest differently across the lifespan cell.com/cancer-cell/fu… Cancer Cell Razelle Kurzrock, MD Vivek Subbiah, MD

🚨Hot off the press👉Pleased to share with the 🌎 our commentary published in Cancer Cell Cell 👉Precision oncology across the ages: Impact on children, adolescents, and young adults 👉#PrecisionOncology Is Age & Tissue-Agnostic #RET #NTRK #BRAF #Precisionmedicine

Feasibility of structuring electronic health record data to facilitate real-world data research: ICAREdata methods applied to multicenter #cancer clinical trials. acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… ACS Journal Cancer CA: A Cancer Journal for Clinicians #CancerResearch #ClinicalTrials #MedTech Dana-Farber

Trastuzumab deruxtecan in HER2+ advanced mCRC The Lancet Oncology doi.org/10.1016/S1470-… 🔎DESTINY-CRC02 phs 2, 122 pts 👉5·4 & 6·4 mg/kg 👉ORR 37·8% & 27·5% 👉mPFS 5·8 & 5·5 mo 👉mOS 13·4 mo & NE 🧐support approval for pts with HER2-positive solid tumours ESMO - Eur. Oncology

📣 ATTENTION TRAINEES! If you’re a trainee interested in Neuroendocrine Neoplasms, I really hope to see you at the NANETS annual multi-disciplinary symposium. ⏱️Nov 21-23,2024 📍Chicago, IL REGISTRATION IS OPEN!! We are planning to organize a special meet-up to foster

Alternating gemcitabine/nab-paclitaxel and gemcitabine vs continuous gemcitabine/nab-paclitaxel after induction Tx of #PDAC The Lancet Oncology doi.org/10.1016/S2468-… 🔎 ALPACA phs 2, 325 pts 👉Similar OS, but improved tolerability 🧐Alternating schedule may be considered ESMO - Eur. Oncology

As we observe #ChildhoodCancerAwarenessMonth, let’s honor the children we’ve lost and recognize the bravery and resilience of those facing cancer. Join me in our fight against childhood cancer and supporting these courageous children and families. #CCAM #ChildhoodCancer

Run #Barcelona 🇪🇸 with OncoAlert and meet your heroes. I did! Shaalan Beg MD MBA FASCO Dr. Nina Niu Sanford Tim Brown, MD MSCE

“The number needed to treat (NNT) to prevent one distant recurrence is 37 (100/2.7) for ribociclib, and estimated cost of around $400,000, for 3 years of therapy for one individual patient, and the cost to prevent one distant disease-free recurrence is $14.8 million.”

My second book “THE CANCER JOURNEY” launches 9/24/24 & is available to pre-order a.co/d/f0mwZCZ I leverage storytelling to explain & simplify everything related to cancer from A-Z; written in an easy to read & understand language so it reaches everyone. Check it out.

Honored to ask to be a part of this video discussing ASCO GI & why I attend year after year. For me it’s about learning and networking! Then as a patient advocate bringing that back to the communities I work with every day! #GI25 #crcsm Emil Lou, MD, PhD, FACP Rachna Shroff, MD, MS, FASCO Robin Zon, MD, FACP, FASCO

Thank you TIME for highlighting our work in Kidney Cancer at Dana-Farber and Dana-Farber Lank Center for Genitourinary Oncology time.com/7018184/kidney…

Big congrats to Laura Dawson & team for completing this symptom-based, palliative radiotherapy RCT! 8Gy x 1 ~whole liver RT improves pain in 67% Agree that all patients fitting study criteria should be offered this simple, convenient, safe & cost-effective treatment.